Skip to main content
SpringerLink
Log in

Does the addition of erlotinib to gemcitabine improve outcome in patients with advanced pancreatic cancer?

  • Practice Point
  • Published:

From Nature Clinical Practice Oncology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cunningham D et al. (2005) Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer [abstract #PS11]. Eur J Cancer Suppl 3: a12

    Google Scholar 

  2. Herrmann R et al. (2007) Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25: 2212–2217

    Article  CAS  Google Scholar 

  3. Oettle H et al. (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer. JAMA 297: 267–277

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. H Oettle is an Associate Professor and A Hilbig is a Clinical Research Fellow in the Department of Medical Oncology and Hematology at the Charité School of Medicine, Berlin, Germany.,

    Helmut Oettle & Andreas Hilbig

Authors
  1. Helmut Oettle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas Hilbig
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Helmut Oettle.

Ethics declarations

Competing interests

H Oettle has received speakers' bureau honoraria from Roche and Lilly and grant/research support from Roche, Lilly and Sanofi Aventis. A Hilbig declared no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oettle, H., Hilbig, A. Does the addition of erlotinib to gemcitabine improve outcome in patients with advanced pancreatic cancer?. Nat Rev Clin Oncol 4, 686–687 (2007). https://doi.org/10.1038/ncponc0960

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0960

  • Springer Nature Limited

Search

Navigation